The Opioid Is In The Mail?
Executive Summary
The US Postal Service is suddenly a key cog in the US public health infrastructure – but don’t expect FDA to mandate mail-back packaging on opioids right away.
You may also be interested in...
US FDA Considering Opioid Mail-Back Envelope Mandate, But Industry Has Heard This Before
Sponsors would be required to furnish patients with pre-paid envelopes to mail back unused opioid medications for disposal. Comments on FDA's proposal could follow industry concerns about burden on health care system voiced when the idea was floated in 2018.
FDA Exploring Partnerships As Alternative To REMS Mandate For Opioid Education
The US FDA is continuing to think through mechanisms to make opioid prescriber education mandatory – either separate from or in addition to relying on its REMS authority.
US FDA Punts To Congress On CBD: Rx Topics Remain Outside Political Spotlight
FDA is formally asking Congress to weigh in on the best approach to regulate CBD in consumer products. That provides another target for legislative attention that may mean that FDA’s core drug regulatory activities stay comfortably out of the spotlight.